H. Moore Arnold

TL;DR: In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner, accompanied by a slowing of clinical decline measured by Clinical Dementia Rating—Sum of Boxes and Mini Mental State Examination scores.

TL;DR: This corrects the article to show that the method used to derive the H2O2 “spatially aggregating force” is based on a two-step process, not a single step, like in the previous version of this paper.

TL;DR: Compound 10a is a potent γ-secretase modulator, which lowered Aβ42, increased Aβ38, but had little to no effect on Aβ40 levels both in vitro and in vivo, and demonstrated excellent pharmacokinetic parameters in multiple species.

TL;DR: It is reported that after interruption of sensory axons in dorsal roots, systemic treatment with a naturally occurring growth factor, artemin (ARTN), promotes regeneration of these axons 3–4 cm away from their original target region in the brainstem, where they reestablish functional connections.

TL;DR: Starting from literature examples of nonsteroidal anti-inflammatory drugs (NSAIDs)-type carboxylic acid γ-secretase modulators (GSMs) and using a scaffold design approach, the discovery of a novel chemical series, represented by 6b, having improved brain penetration, is made.